Company intelligence / Profile preview
BioMolecular Products, Inc.
Bradford, Massachusetts, United Statesbiomolecularproducts.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The company’s Lym-X-Sorb® technology has demonstrated improved choline status in children with cystic fibrosis in a randomized controlled trial, and enabled complete responses in four out of eighteen neuroblastoma patients at high dosing levels with an oral powder formulation of fenretinide. The technology improves solubilization, stability, and bioavailability of poorly soluble drugs[6].
- Therapeutic areas
- OncologyRare DiseasesOther
- Modalities
- Lipid-based drug delivery systems (notably Lym-X-Sorb®)Small molecules (as compatible payloads)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on BioMolecular Products, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioMolecular Products, Inc..